- Home
- GAME vs CVKD Comparison
GAME vs CVKD Comparison
Compare GAME & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAME
- CVKD
- Stock Information
- Founded
- GAME 2011
- CVKD 2022
- Country
- GAME United States
- CVKD United States
- Employees
- GAME N/A
- CVKD N/A
- Industry
- GAME
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- GAME
- CVKD Health Care
- Exchange
- GAME Nasdaq
- CVKD Nasdaq
- Market Cap
- GAME 27.2M
- CVKD 29.5M
- IPO Year
- GAME 2009
- CVKD 2023
- Fundamental
- Price
- GAME $1.54
- CVKD $12.68
- Analyst Decision
- GAME Strong Buy
- CVKD Strong Buy
- Analyst Count
- GAME 3
- CVKD 1
- Target Price
- GAME $3.67
- CVKD $32.00
- AVG Volume (30 Days)
- GAME 1.4M
- CVKD 33.5K
- Earning Date
- GAME 08-13-2025
- CVKD 08-06-2025
- Dividend Yield
- GAME N/A
- CVKD N/A
- EPS Growth
- GAME N/A
- CVKD N/A
- EPS
- GAME N/A
- CVKD N/A
- Revenue
- GAME $99,579,536.00
- CVKD N/A
- Revenue This Year
- GAME $6.08
- CVKD N/A
- Revenue Next Year
- GAME $21.94
- CVKD N/A
- P/E Ratio
- GAME N/A
- CVKD N/A
- Revenue Growth
- GAME 77.06
- CVKD N/A
- 52 Week Low
- GAME $0.50
- CVKD $5.70
- 52 Week High
- GAME $1.64
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- GAME 84.05
- CVKD 47.47
- Support Level
- GAME $0.73
- CVKD $11.00
- Resistance Level
- GAME $0.97
- CVKD $13.24
- Average True Range (ATR)
- GAME 0.12
- CVKD 1.13
- MACD
- GAME 0.06
- CVKD 0.20
- Stochastic Oscillator
- GAME 85.15
- CVKD 72.33
About GAME GameSquare Holdings Inc.
GameSquare Holdings Inc is engaged to revolutionize the way brands and game publishers connect with hard-to-reach Gen Z, Gen Alpha, and Millennial audiences. Its next generation media, entertainment, and technology help creators and maximize its brand partners return on investment. Its purpose-built platform, provide marketing and creative services, offer data and analytics solutions, and amplify awareness through FaZe Clan.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.